Phacilitate Leaders World

Phacilitate Leaders World & World Stem Cell Summit 2019 Agenda

Phacilitate Leaders World & World Stem Cell Summit 2019 Agenda

Loading
  1. Registration for Phacilitate Leaders World and World Stem Cell Summit opens
  1. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  2. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  3. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  4. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  5. Joint Pre-conference super plenary - The next 15 years for advanced therapies

  1. Drinks reception
  1. Registration for Phacilitate Leaders World and World Stem Cell Summit opens
  1. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

  2. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

  3. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

  4. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

  5. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

  6. Phacilitate Leaders World Plenary

    WHAT IS THE CURRENT STATE OF PLAY IN ADVANCED THERAPIES?

  1. Word Stem Cell Summit Plenary

    THE ALPHA SESSION

  2. Word Stem Cell Summit Plenary

    THE ALPHA CLINIC

  3. Word Stem Cell Summit Plenary

    THE ALPHA CLINIC

  1. Morning coffee break
  1. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

  2. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

  3. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

  4. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

  5. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

  6. Cellular immunotherapies

    The next breakthrough: challenging the status quo with allogeneic therapies

  1. Manufacturing for commercialisation

    Lowering cost of goods: The evolution to making advanced therapies affordable and practical (Partnered with RMMS)

  2. Manufacturing for commercialisation

    Lowering cost of goods

  3. Manufacturing for commercialisation

    Lowering cost of goods

  4. Manufacturing for commercialisation

    Lowering cost of goods

  5. Manufacturing for commercialisation

    Lowering cost of goods

  6. Manufacturing for commercialisation

    Lowering cost of goods

  1. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

  2. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

  3. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

  4. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

  5. Gene therapy

    Enabling the next generation of gene therapy products delivery: exciting developments & innovation

  1. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

  2. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

  3. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

  4. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

  5. Standards workshops

    Easing the Apheresis Burden: The Case for Industry Standardization in Cellular Starting Material Collection

  1. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

  2. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

  3. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

  4. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

  5. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

  6. Supply chain

    Designing and implementing efficient, scalable cell & gene supply chain strategy to aid globalisation Partnered with RMMS

  1. Discovery & translation

    The impact of converging technologies for stem cell research and translation

  2. Discovery & translation

    The impact of converging technologies for stem cell research and translation

  3. Discovery & translation

    The impact of converging technologies for stem cell research and translation

  4. Discovery & translation

    The impact of converging technologies for stem cell research and translation

  5. Discovery & translation

    The impact of converging technologies for stem cell research and translation

  1. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

  2. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

  3. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

  4. Perspectives on the regenerative medicine ecosystem

    Latin America & The Caribbean: expanding markets, ethics and policy perspectives

  1. Lunch break
  1. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

  2. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

  3. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

  4. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

  5. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

  6. Cellular immunotherapies

    Improving CAR-T safety & reducing toxicity

  1. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

  2. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

  3. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

  4. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

  5. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

  6. Manufacturing for commercialisation

    Moving towards globalization and scale-up of cell therapy GMP manufacturing

  1. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

  2. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

  3. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

  4. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

  5. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

  6. Gene therapy

    Overcoming obstacles in vivo: the road to commercial viability and continuing clinical success in viral gene therapy

  1. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

  2. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

  3. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

  4. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

  5. Standards workshops

    Forging the path to standardised clinical shipments; logistics and delivery of products through multiple silos

  1. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

  2. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

  3. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

  4. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

  5. Supply chain

    Extending Shelf Life and Minimizing Logistics Challenges in Starting Materials for clinical and commercial development

  1. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

  2. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

  3. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

  4. Discovery & translation

    Disease Modeling: Organoids & Body-on-a-Chip

  1. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

  2. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

  3. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

  4. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

  5. Perspectives on the regenerative medicine ecosystem

    Bringing order to the wild west: regulatory enforcement, law suits and ethical considerations for stem cells in clinical practice

  1. Afternoon coffee break
  1. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

  2. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

  3. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

  4. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

  5. Cellular immunotherapies

    CAR/TCR Investment: What is the next blockbuster technology I should be investing in?

  1. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

  2. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

  3. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

  4. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

  5. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

  6. Manufacturing for commercialisation

    Strategic approaches towards cell and gene therapy product commercialisation

  1. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

  2. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

  3. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

  4. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

  5. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

  6. Gene therapy

    Revolutionising healthcare: utilising gene editing tools for improving in vivo and ex vivo gene therapy

  1. Standards workshops

    Mitigating clinical and business risk: standardising manufacturing practice in cell and gene therapiesPartnered with RMMS

  2. Standards workshops

    Mitigating clinical and business risk: standardising manufacturing practice in cell and gene therapiesPartnered with RMMS

  3. Standards workshops

    Mitigating clinical and business risk: standardising manufacturing practice in cell and gene therapiesPartnered with RMMS

  1. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

  2. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

  3. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

  4. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

  5. Discovery & translation

    Beyond traditional bioengineering technologies: Bioprinting, Bioink & Xeno (Partnered with RMMS)

  1. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

  2. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

  3. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

  4. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

  5. Regenerative medicine in the clinic

    Orthopaedics & Sports Medicine: Stem cell and regenerative medicine treatments

  1. Twilight roundtables

    In house or outsourced manufacturing – what are the key driving factors for this decision?
  2. Twilight roundtables

    High Quality Raw Materials from Clinical to Commercial Phase
  3. Twilight roundtables

    Cost drivers in Mesenchymal Stem/Stromal Cell manufacturing, and technology strategies to address them
  4. Twilight roundtables

    Challenges in allogenaic stem cell therapy: delivery, engraftment, efficacy and durability
  5. Twilight roundtables

    Addressing pain points in scale-up viral vector production – commercial and technical perspectives
  6. Twilight roundtables

    Are serum free conditions the answer to standardisation, quality control and lowering COG’s for starting materials?
  1. Registration for Phacilitate Leaders World and World Stem Cell Summit
  1. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

  2. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

  3. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

  4. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

  5. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

  6. Phacilitate Leaders World Plenary

    Achieving global scale in advanced therapies: harmonizing regulatory environments around the world

  1. Morning coffee break
  1. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

  2. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

  3. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

  4. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

  5. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

  6. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

  7. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part One

  1. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

  2. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

  3. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

  4. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

  5. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

  6. Manufacturing for commercialisation

    How do you design and implement an efficient process control strategy to ensure quality control?

  1. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

  2. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

  3. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

  4. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

  5. Healthcare

    Moving mainstream: lessons and best practices for integrating cell & gene therapies into healthcare

  1. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

  2. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

  3. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

  4. Biotech Bootcamp

    Building a successful spin-out: Defining your business & IP strategy to move cell and gene therapies into the clinic and beyond

  1. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

  2. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

  3. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

  4. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

  5. Cord blood & Perinatal Stem Cells

    WELCOME SESSION: Examining the status of cord blood and perinatal tissue today - recent developments, bottlenecks and future direction

  1. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

  2. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

  3. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

  4. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

  5. Discovery & translation

    Exosome Breakthroughs (Partnered with RMMS)

  1. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

  2. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

  3. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

  4. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

  5. Regenerative medicine in the clinic

    Treating wounded warriors using regenerative medicine

  1. Lunch break
  1. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

  2. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

  3. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

  4. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

  5. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

  6. Cellular immunotherapies

    Changing cancer treatment forever: Innovation in autologous cellular immunotherapies - Part Two

  1. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

  2. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

  3. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

  4. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

  5. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

  6. Manufacturing for commercialisation

    The manufacturing strategy conundrum: work with a CMO or do all your manufacturing in house for cell and gene therapies?

  1. Healthcare

    The next phase of data management, transfer and analysis

  2. Healthcare

    The next phase of data management, transfer and analysis

  3. Healthcare

    The next phase of data management, transfer and analysis

  4. Healthcare

    The next phase of data management, transfer and analysis

  5. Healthcare

    The next phase of data management, transfer and analysis

  6. Healthcare

    The next phase of data management, transfer and analysis

  1. Biotech Bootcamp

    Attracting investment: valuations, alternative funding sources & investor profiling

  2. Biotech Bootcamp

    Attracting investment: valuations, alternative funding sources & investor profiling

  3. Biotech Bootcamp

    Attracting investment: valuations, alternative funding sources & investor profiling

  4. Biotech Bootcamp

    Attracting investment: valuations, alternative funding sources & investor profiling

  1. Automation

    Getting technical: Selecting an automation solution

  2. Automation

    Getting technical: Selecting an automation solution

  3. Automation

    Getting technical: Selecting an automation solution

  4. Automation

    Getting technical: Selecting an automation solution

  5. Automation

    Getting technical: Selecting an automation solution

  6. Automation

    Getting technical: Selecting an automation solution

  1. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space

  2. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space

  3. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space

  4. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space

  5. Cord blood & Perinatal Stem Cells

    NEW SCIENCE SESSION! Innovators within the cord blood and perinatal tissue space - Part 2

  1. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

  2. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

  3. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

  4. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

  5. Discovery & translation

    Neurology and aging diseases: Giving neurology patients new hope through stem cell research

  1. Regenerative medicine in the clinic

    Adipose Tissue and SVF in the Clinic

  2. Regenerative medicine in the clinic

    Adipose Tissue and SVF in the Clinic

  3. Regenerative medicine in the clinic

    Adipose Tissue and SVF in the Clinic

  4. Regenerative medicine in the clinic

    Adipose Tissue and SVF in the Clinic

  5. Regenerative medicine in the clinic

    Adipose Tissue and SVF in the Clinic

  1. Afternoon coffee break
  1. Cellular immunotherapies

    The next phase of data management, transfer and analysis in cellular immunotherapies

  2. Cellular immunotherapies

    The next phase of data management, transfer and analysis in cellular immunotherapies

  3. Cellular immunotherapies

    The next phase of data management, transfer and analysis in cellular immunotherapies

  4. Cellular immunotherapies

    The next phase of data management, transfer and analysis in cellular immunotherapies

  5. Cellular immunotherapies

    The next phase of data management, transfer and analysis in cellular immunotherapies

  1. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

  2. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

  3. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

  4. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

  5. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

  6. Manufacturing for commercialisation

    Key considerations for gene therapy manufacture; scale-up for GMP viral vectors

  1. Healthcare

    Standardising Clinical Centres of Excellence

  2. Healthcare

    Standardising Clinical Centres of Excellence

  3. Healthcare

    Standardising Clinical Centres of Excellence

  4. Healthcare

    Standardising Clinical Centres of Excellence

  5. Healthcare

    Standardising Clinical Centres of Excellence

  6. Healthcare

    Standardising Clinical Centres of Excellence

  1. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

  2. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

  3. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

  4. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

  5. Biotech Bootcamp

    How to define and identify key partnerships to accelerate commercialisation

  1. Cord blood & Perinatal Stem Cells

    Clinical tirals to commerial use - expansion, bioprocessing and recent technology

  2. Cord blood & Perinatal Stem Cells

    Clinical tirals to commerial use - expansion, bioprocessing and recent technology

  3. Cord blood & Perinatal Stem Cells

    Clinical tirals to commerial use - expansion, bioprocessing and recent technology

  4. Cord blood & Perinatal Stem Cells

    Clinical tirals to commerial use - expansion, bioprocessing and recent technology

  5. Cord blood & Perinatal Stem Cells

    Clinical tirals to commerial use - expansion, bioprocessing and recent technology

  1. Discovery & translation

    Stem cells - the curative frontier for diabetes and other autoimmune disorders

  2. Discovery & translation

    Stem cells - the curative frontier for diabetes and other autoimmune disorders

  3. Discovery & translation

    Stem cells - the curative frontier for diabetes and other autoimmune disorders

  4. Discovery & translation

    Stem cells - the curative frontier for diabetes and other autoimmune disorders

  5. Discovery & translation

    Stem cells - the curative frontier for diabetes and other autoimmune disorders

  1. Regenerative medicine in the clinic

    NEED TO KNOW! Legal and regulatory issues impacting clinicians

  2. Regenerative medicine in the clinic

    NEED TO KNOW! Legal and regulatory issues impacting clinicians

  3. Regenerative medicine in the clinic

    NEED TO KNOW! Legal and regulatory issues impacting clinicians

  4. Regenerative medicine in the clinic

    NEED TO KNOW! Legal and regulatory issues impacting clinicians

  5. Regenerative medicine in the clinic

    NEED TO KNOW! Legal and regulatory issues impacting clinicians

  1. Conference Digest with PCT: What are the outcomes from the past 2 days?
  1. Registration for Phacilitate Leaders World and World Stem Cell Summit
  1. Pre-clinical/Clinical Innovation

    Biotech showcase session: where is the next big innovation going to come from in cell, gene and immunooncology?

  2. Pre-clinical/Clinical Innovation

    Biotech showcase session: where is the next big innovation going to come from in cell, gene and immunooncology?

  3. Pre-clinical/Clinical Innovation

    Biotech showcase session: where is the next big innovation going to come from in cell, gene and immunooncology?

  4. Pre-clinical/Clinical Innovation

    Biotech showcase session: where is the next big innovation going to come from in cell, gene and immunooncology?

  5. Pre-clinical/Clinical Innovation

    Biotech showcase session: where is the next big innovation going to come from in cell, gene and immunooncology?

  6. Pre-clinical/Clinical Innovation

    Biotech showcase session: where is the next big innovation going to come from in cell, gene and immunooncology?

  1. Manufacturing for commercialisation

    Building a Sustainable Academic Engine: the bridge between academic innovation and commercialized products for advanced therapies

  2. Manufacturing for commercialisation

    Building a Sustainable Academic Engine: the bridge between academic innovation and commercialized products for advanced therapies

  3. Manufacturing for commercialisation

    Building a Sustainable Academic Engine: the bridge between academic innovation and commercialized products for advanced therapies

  4. Manufacturing for commercialisation

    Building a Sustainable Academic Engine: the bridge between academic innovation and commercialized products for advanced therapies

  5. Manufacturing for commercialisation

    Building a Sustainable Academic Engine: the bridge between academic innovation and commercialized products for advanced therapies

  6. Manufacturing for commercialisation

    Building a Sustainable Academic Engine: the bridge between academic innovation and commercialized products for advanced therapies

  1. Cord blood & Perinatal Stem Cells

    The Missing Piece of the Cord Blood Puzzle: Education and Advocacy

  2. Cord blood & Perinatal Stem Cells

    Patient Advocacy in the Cord Blood Space

  3. Cord blood & Perinatal Stem Cells

    Patient Advocacy in the Cord Blood Space

  4. Cord blood & Perinatal Stem Cells

    Patient Advocacy in the Cord Blood Space

  5. Cord blood & Perinatal Stem Cells

    Patient Advocacy in the Cord Blood Space